Literature DB >> 24337308

[Bullous pemphigoid].

F Schulze1, M Kasperkiewicz, D Zillikens, E Schmidt.   

Abstract

Pemphigoid diseases are a group of autoimmune disorders characterized by subepidermal blistering and autoantibodies against structural proteins of the dermal-epidermal junction. In bullous pemphigoid, the most common subepidermal blistering autoimmune disease, antibodies are directed against the hemidesmosomal antigens BP180 (collagen type XVII) and BP230. Bullous pemphigoid typically presents with severe pruritus and tense blisters accompanied by erosions and crusts in elderly patients. Diagnostic landmarks are the detection of linear IgG and/or C3 deposits at the dermo-epidermal junction by direct immunofluorescence microscopy of a perilesional biopsy and the detection of serum autoantibodies by indirect immunofluorescence microscopy on human salt-split skin and ELISA employing recombinant immunodominant fragments of BP180 and BP230. Treatment options include topical (class IV) and/or systemic corticosteroids, frequently combined with immunomodulatory agents like dapsone and tetracyclines or immunosuppressants such as methotrexate and azathioprine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337308     DOI: 10.1007/s00105-013-2599-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  39 in total

1.  Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases.

Authors:  Detlef Zillikens; Kurt Derfler; Rüdiger Eming; Gerhard Fierlbeck; Matthias Goebeler; Michael Hertl; Silke C Hofmann; Franz Karlhofer; Ocko Kautz; Martin Nitschke; Andreas Opitz; Sven Quist; Christian Rose; Stefan Schanz; Enno Schmidt; Iakov Shimanovich; Michael Michael; Fabian Ziller
Journal:  J Dtsch Dermatol Ges       Date:  2007-10       Impact factor: 5.584

Review 2.  Clinical features and practical diagnosis of bullous pemphigoid.

Authors:  Enno Schmidt; Rocco della Torre; Luca Borradori
Journal:  Dermatol Clin       Date:  2011-07       Impact factor: 3.478

Review 3.  Pathogenesis of bullous pemphigoid.

Authors:  Hideyuki Ujiie; Wataru Nishie; Hiroshi Shimizu
Journal:  Dermatol Clin       Date:  2011-07       Impact factor: 3.478

4.  Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice.

Authors:  Misa Hirose; Andreas Recke; Tina Beckmann; Atsushi Shimizu; Akira Ishiko; Katja Bieber; Jürgen Westermann; Detlef Zillikens; Enno Schmidt; Ralf J Ludwig
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

Review 5.  Pemphigoid diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Lancet       Date:  2012-12-11       Impact factor: 79.321

6.  Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.

Authors:  E Schmidt; K Obe; E B Bröcker; D Zillikens
Journal:  Arch Dermatol       Date:  2000-02

7.  Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.

Authors:  Yohei Iwata; Kazuhiro Komura; Masanari Kodera; Toshikazu Usuda; Yoko Yokoyama; Toshihide Hara; Eiji Muroi; Fumihide Ogawa; Motoi Takenaka; Shinichi Sato
Journal:  Arch Dermatol       Date:  2008-01

8.  Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.

Authors:  Philippe Bernard; Ziad Reguiai; Emmanuelle Tancrède-Bohin; Nadege Cordel; Patrice Plantin; Christine Pauwels; Loïc Vaillant; Florent Grange; Marie-Aleth Richard-Lallemand; Bruno Sassolas; Jean-Claude Roujeau; Catherine Lok; Catherine Picard-Dahan; Olivier Chosidow; Fabien Vitry; Pascal Joly
Journal:  Arch Dermatol       Date:  2009-05

9.  Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls.

Authors:  L Büdinger; L Borradori; C Yee; R Eming; S Ferencik; H Grosse-Wilde; H F Merk; K Yancey; M Hertl
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

10.  Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy.

Authors:  Nina van Beek; Kristin Rentzsch; Christian Probst; Lars Komorowski; Michael Kasperkiewicz; Kai Fechner; Inga M Bloecker; Detlef Zillikens; Winfried Stöcker; Enno Schmidt
Journal:  Orphanet J Rare Dis       Date:  2012-08-09       Impact factor: 4.123

View more
  3 in total

Review 1.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

2.  [85-year-old male with cutaneous blisters : Preparation for the medical specialist examination: Part 25].

Authors:  Mareike Witte; Enno Schmidt; Ralf Ludwig
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

3.  [Localized bullous pemphigoid triggered by erysipelas].

Authors:  F B Löffel; M Stücker
Journal:  Hautarzt       Date:  2016-10       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.